博文
研究热点与前沿：前列腺癌的流行病学、治疗方法与指南
|||
利用汤森路透科技集团的基本科学指标库（Essential Science Indicators）2004－2010间的高被引论文及其同被引聚类分析，通过同被引而密切关联的相关论文聚类形成若干个科学研究领域，由此绘制科学文献所反映的科学研究结构地图，讨论科学发展的基本格局。通过研究和揭示科学结构及其演化，为各领域研究提供一种思考问题、发现潜在交叉学科、“热点”领域。
/******************************************************************/
第一部分：RA 5 的基本信息
/******************************************************************/
RA ID: 5 | |||||
RA的名称 | 前列腺癌的流行病学、治疗方法与指南 | ||||
RA的关键词 | prostate cancer; after radical prostatectomy; androgen deprivation; locally advanced prostate cancer; androgen deprivation therapy; locally advanced prostate; radical prostatectomy; advanced prostate cancer; radiation therapy; prostate cancer after radical prostatectomy | ||||
包含RF数(Hot RF数) | 核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | |
6(3) | 63 | 3538 | 6328 | 2006.7 | |
该RA中包含RF的图谱 | |||||
前列腺癌的放射治疗与去雄激素治疗以及相关的治疗指南 | |||||
RA概述 | |||||
前列腺癌（prostatic cancer）是男性生殖系最常见的恶性肿瘤，发病随年龄而增长，其发病率有明显的地区差异，欧美地区较高。在前列腺癌的治疗中，放射治疗具有重要的作用。早期前列腺癌放射治疗可达到根治的目的，疗效与前列腺癌根治术相近。局部晚期前列腺癌的治疗则以放射治疗为主，已有远处转移的前列腺癌放疗也可取得减轻症状，改善生存质量等姑息疗效。放疗具有疗效好，适应证广，并发症较少和治疗后病人生存质量高等优点。 迄今，内分泌治疗是晚期前列腺癌的主要治疗方法。抗雄激素类药物可与内源性雄激素在靶器官上竞争受体结合，在胞质内通过与双氢睾丸酮受体结合，抑制双氢睾丸酮进入细胞核，从而阻断雄激素对前列腺细胞的作用，达到治疗的目的。 | |||||
/******************************************************************/
第二部分：RA 5 包含的6个RF的基本信息
/******************************************************************/
RF ID: 5551 | ||||
核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
39 | 1658 | 3781 | 2007.0 | No |
RF的关键词 | clinically localized prostate cancer; locally advanced prostate cancer (spcg-7/sfuo-3); progressive prostate cancer; node-positive prostate cancer; early prostate cancer | |||
RF ID: 5473 | ||||
核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
9 | 1083 | 1944 | 2005.3 | No |
RF的关键词 | prostate cancer risk; prostate cancer following external beam radiation therapy; prostate cancer prevention trial; life-threatening prostate cancer; pretreatment prostate-specific antigen velocity | |||
RF ID: 6895 | ||||
核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
6 | 294 | 687 | 2007.3 | No |
RF的关键词 | post-salvage radiotherapy prostate cancer-specific survival radical prostatectomy comparison; phase iii postoperative adjuvant radiotherapy; radical prostatectomy compared; pathological t3n0m0 prostate cancer significantly reduces risk | |||
RF ID: 7689 | ||||
核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
5 | 691 | 1264 | 2004.8 | Yes |
RF的关键词 | clinically localized prostate cancer; early prostate cancer; 20-year outcomes following conservative management; will rogers phenomenon; watchful waiting | |||
RF ID: 12278 | ||||
核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
2 | 216 | 294 | 2007.5 | Yes |
RF的关键词 | clinically localized prostate cancer 2007 update management guideline; eau guidelines | |||
RF ID: 16037 | ||||
核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
2 | 255 | 313 | 2006.5 | Yes |
RF的关键词 | stages t1-t2 prostate cancer; clinically localized prostate cancer; defining biochemical failure following radiotherapy; rtog-astro phoenix consensus conference; permanent seed implantation | |||
/******************************************************************/
第三部分：6个RF的核心论文详细列表
/******************************************************************/
RF ID | 核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
5551 | 39 | 1658 | 3781 | 2007.0 | No |
RF的关键词 | clinically localized prostate cancer; locally advanced prostate cancer (spcg-7/sfuo-3); progressive prostate cancer; node-positive prostate cancer; early prostate cancer | ||||
论文题目 | 被引 | 年份 | 刊名 | 第一作者 | 第一机构、国家 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer - a randomized controlled trial | 284 | 2004 | JAMA-J AM MED ASSN | D'AMICO AV | Brigham & Womens Hosp, USA |
comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate - a randomized controlled trial | 274 | 2005 | JAMA-J AM MED ASSN | ZIETMAN AL | Harvard Univ, USA |
risk of fracture after androgen deprivation for prostate cancer | 252 | 2005 | N ENGL J MED | SHAHINIAN VB | Univ Texas, USA |
denosumab in postmenopausal women with low bone mineral density | 241 | 2006 | N ENGL J MED | MCCLUNG MR | Oregon Osteoporosis Ctr, USA |
androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase iii rtog 85-31 | 225 | 2005 | INT J RADIAT ONCOL BIOL PHYS | PILEPICH MV | Univ Calif Los Angeles, USA |
diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer | 211 | 2006 | J CLIN ONCOL | KEATING NL | Harvard Univ, USA |
a single-dose placebo-controlled study of amg 162, a fully human monoclonal antibody to rankl, in postmenopausal women | 180 | 2004 | J BONE MINER RES | BEKKER PJ | Amgen Inc, USA |
dose-response in radiotherapy for localized prostate cancer: results of the dutch multicenter randomized phase iii trial comparing 68 gy of radiotherapy with 78 gy | 159 | 2006 | J CLIN ONCOL | PEETERS STH | Antoni van Leeuwenhoek Hosp, Netherlands |
immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy | 142 | 2006 | LANCET ONCOL | MESSING EM | Univ Rochester, USA |
a study of the biological receptor activator of nuclear factor-kappa b ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer | 122 | 2006 | CLIN CANCER RES | BODY JJ | Inst Jules Bordet, Belgium |
short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the trans-tasman radiation oncology group 96.01 randomised controlled trial | 119 | 2005 | LANCET ONCOL | DENHAM JW | Univ Newcastle, Australia |
regulation of cancer cell migration and bone metastasis by rankl | 118 | 2006 | NATURE | JONES DH | Austrian Acad Sci, Austria |
influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions | 111 | 2007 | J CLIN ONCOL | D'AMICO AV | Brigham & Womens Hosp, USA |
metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy | 99 | 2006 | J CLIN ONCOL | BRAGA-BASARIA M | Johns Hopkins Univ, USA |
long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer | 97 | 2006 | J UROL | ZELEFSKY MJ | Mem Sloan Kettering Canc Ctr, USA |
bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer | 91 | 2006 | BJU INT | MCLEOD DG | Walter Reed Army Med Ctr, USA |
androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality | 86 | 2007 | J NAT CANCER INST | TSAI HK | Harvard Univ, USA |
insulin sensitivity during combined androgen blockade for prostate cancer | 85 | 2006 | J CLIN ENDOCRINOL METAB | SMITH MR | Massachusetts Gen Hosp, USA |
long-term results of the m. d. anderson randomized dose-escalation trial for prostate cancer | 82 | 2008 | INT J RADIAT ONCOL BIOL PHYS | KUBAN DA | Univ Texas MD Anderson Canc Ctr, USA |
escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the mrc rt01 randomised controlled trial | 80 | 2007 | LANCET ONCOL | DEARNALEY DP | Inst Canc Res, England |
androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer | 76 | 2007 | CANCER | SAIGAL CS | Univ Calif Los Angeles, USA |
initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an american society of clinical oncology practice guideline | 71 | 2007 | J CLIN ONCOL | LOBLAW DA | Amer Soc Clin Oncol, USA |
short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of rtog 8610 | 62 | 2008 | J CLIN ONCOL | ROACH M | Univ Calif San Francisco, USA |
androgen suppression and radiation vs radiation alone for prostate cancer - a randomized trial | 61 | 2008 | JAMA-J AM MED ASSN | D'AMICO AV | Brigham & Womens Hosp, USA |
randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer | 60 | 2007 | J CLIN ONCOL | MICHAELSON MD | Massachusetts Gen Hosp, USA |
denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis | 52 | 2008 | ARTHRITIS RHEUM | COHEN SB | Metroplex Clin Res Ctr, USA |
survival following primary androgen deprivation therapy among men with localized prostate cancer | 41 | 2008 | JAMA-J AM MED ASSN | LU-YAO GL | Univ Med & Dent New Jersey, USA |
ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase iii trial of the duration of elective androgen deprivation in locally advanced prostate cancer | 36 | 2008 | J CLIN ONCOL | HORWITZ EM | Fox Chase Canc Ctr, USA |
endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (spcg-7/sfuo-3): an open randomised phase iii trial | 35 | 2009 | LANCET | WIDMARK A | Umea Univ, Sweden |
effects of denosumab on bone mineral density and bone turnover in postmenopausal women | 32 | 2008 | J CLIN ENDOCRINOL METAB | BONE HG | Michigian Bone & Mineral Clin, USA |
effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial | 32 | 2008 | BONE | MILLER PD | Colorado Ctr Bone Res, USA |
randomized phase ii trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates | 30 | 2009 | J CLIN ONCOL | FIZAZI K | Univ Paris 11, France |
denosumab for prevention of fractures in postmenopausal women with osteoporosis | 26 | 2009 | N ENGL J MED | CUMMINGS SR | 185 Berry St Lobby 4, USA |
comparison of the effect of denosumab and alendronate on bmd and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial | 26 | 2009 | J BONE MINER RES | BROWN JP | CHUL, Canada |
denosumab in men receiving androgen-deprivation therapy for prostate cancer | 25 | 2009 | N ENGL J MED | SMITH MR | Massachusetts Gen Hosp, USA |
cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: rtog 85-31 | 22 | 2009 | J CLIN ONCOL | EFSTATHIOU JA | Massachusetts Gen Hosp, USA |
duration of androgen suppression in the treatment of prostate cancer | 17 | 2009 | N ENGL J MED | BOLLA M | Grenoble Univ Hosp, France |
a systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma | 12 | 2009 | CANCER TREATMENT REV | SHELLEY MD | Velindre NHS Trust, Wales |
cause of death in older men after the diagnosis of prostate cancer | 7 | 2009 | J AMER GERIAT SOC | KETCHANDJI M | Sealy Ctr Aging, USA |
RF ID | 核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
5473 | 9 | 1083 | 1944 | 2005.3 | No |
RF的关键词 | prostate cancer risk; prostate cancer following external beam radiation therapy; prostate cancer prevention trial; life-threatening prostate cancer; pretreatment prostate-specific antigen velocity | ||||
论文题目 | 被引 | 年份 | 刊名 | 第一作者 | 第一机构、国家 |
prevalence of prostate cancer among men with a prostate-specific antigen level <= 4.0 ng per milliliter | 564 | 2004 | N ENGL J MED | THOMPSON IM | SW Oncol Grp SWOG 9217, USA |
preoperative psa velocity and the risk of death from prostate cancer after radical prostatectomy | 309 | 2004 | N ENGL J MED | D'AMICO AV | Brigham & Womens Hosp, USA |
risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy | 273 | 2005 | JAMA-J AM MED ASSN | FREEDLAND SJ | Johns Hopkins Univ Hosp, USA |
the prostate specific antigen era in the united states is over for prostate cancer: what happened in the last 20 years? | 215 | 2004 | J UROL | STAMEY TA | Stanford Univ, USA |
operating characteristics of prostate-specific antigen in men with an initial psa level of 3.0 ng/ml or lower | 174 | 2005 | JAMA-J AM MED ASSN | THOMPSON IM | SW Oncol Grp, USA |
assessing prostate cancer risk: results from the prostate cancer prevention trial | 168 | 2006 | J NAT CANCER INST | THOMPSON IM | Univ Texas, USA |
pretreatment psa velocity and risk of death from prostate cancer following external beam radiation therapy | 125 | 2005 | JAMA-J AM MED ASSN | D'AMICO AV | Brigham & Womens Hosp, USA |
detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability | 100 | 2006 | J NAT CANCER INST | CARTER HB | Johns Hopkins Univ, USA |
systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer | 16 | 2009 | J CLIN ONCOL | VICKERS AJ | Mem Sloan Kettering Canc Ctr, USA |
RF ID | 核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
6895 | 6 | 294 | 687 | 2007.3 | No |
RF的关键词 | post-salvage radiotherapy prostate cancer-specific survival radical prostatectomy comparison; phase iii postoperative adjuvant radiotherapy; radical prostatectomy compared; pathological t3n0m0 prostate cancer significantly reduces risk | ||||
论文题目 | 被引 | 年份 | 刊名 | 第一作者 | 第一机构、国家 |
postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (eortc trial 22911) | 303 | 2005 | LANCET | BOLLA M | Univ Hosp, France |
adjuvant radiotherapy for pathologically advanced prostate cancer - a randomized clinical trial | 211 | 2006 | JAMA-J AM MED ASSN | THOMPSON IM | Univ Texas, USA |
predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy | 86 | 2007 | J CLIN ONCOL | STEPHENSON AJ | Cleveland Clin Fdn, USA |
adjuvant radiotherapy for pathological t3n0m0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial | 40 | 2009 | J UROL | THOMPSON IM | Univ Texas San Antonio, USA |
prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy | 33 | 2008 | JAMA-J AM MED ASSN | TROCK BJ | Johns Hopkins Univ, USA |
phase iii postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pt3 prostate cancer with postoperative undetectable prostate-specific antigen: aro 96-02/auo ap 09/95 | 14 | 2009 | J CLIN ONCOL | WIEGEL T | Univ Hosp Ulm, Germany |
RF ID | 核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
7689 | 5 | 691 | 1264 | 2004.8 | Yes |
RF的关键词 | clinically localized prostate cancer; early prostate cancer; 20-year outcomes following conservative management; will rogers phenomenon; watchful waiting | ||||
论文题目 | 被引 | 年份 | 刊名 | 第一作者 | 第一机构、国家 |
radical prostatectomy versus watchful waiting in early prostate cancer | 516 | 2005 | N ENGL J MED | BILL-AXELSON A | Univ Uppsala Hosp, Sweden |
20-year outcomes following conservative management of clinically localized prostate cancer | 305 | 2005 | JAMA-J AM MED ASSN | ALBERTSEN PC | Univ Connecticut, USA |
natural history of early, localized prostate cancer | 217 | 2004 | JAMA-J AM MED ASSN | JOHANSSON JE | Orebro Univ Hosp, Sweden |
active surveillance for prostate cancer: for whom? | 117 | 2005 | J CLIN ONCOL | KLOTZ L | Univ Toronto, Canada |
prostate cancer and the will rogers phenomenon | 109 | 2005 | J NAT CANCER INST | ALBERTSEN PC | Univ Connecticut, USA |
RF ID | 核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
12278 | 2 | 216 | 294 | 2007.5 | Yes |
RF的关键词 | clinically localized prostate cancer 2007 update management guideline; eau guidelines | ||||
论文题目 | 被引 | 年份 | 刊名 | 第一作者 | 第一机构、国家 |
eau guidelines on prostate cancer | 207 | 2008 | EUR UROL | HEIDENREICH A | Univ Cologne, Germany |
guideline for the management of clinically localized prostate cancer: 2007 update | 87 | 2007 | J UROL | THOMPSON I |
|
RF ID | 核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
16037 | 2 | 255 | 313 | 2006.5 | Yes |
RF的关键词 | stages t1-t2 prostate cancer; clinically localized prostate cancer; defining biochemical failure following radiotherapy; rtog-astro phoenix consensus conference; permanent seed implantation | ||||
论文题目 | 被引 | 年份 | 刊名 | 第一作者 | 第一机构、国家 |
defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the rtog-astro phoenix consensus conference | 246 | 2006 | INT J RADIAT ONCOL BIOL PHYS | ROACH M | Univ Calif San Francisco, USA |
multi-institutional analysis of long-term outcome for stages t1-t2 prostate cancer treated with permanent seed implantation | 67 | 2007 | INT J RADIAT ONCOL BIOL PHYS | ZELEFSKY MJ | Mem Sloan Kettering Canc Ctr, USA |
https://wap.sciencenet.cn/blog-280034-687697.html
上一篇：研究热点与前沿：成人神经干细胞对于成年神经再生的重要意义
下一篇：研究热点：雷帕霉素靶蛋白(mTOR)、磷酸肌醇3激酶(pi3k)信号通路
